88 related articles for article (PubMed ID: 22541095)
1. [Clinical significance of serum vascular endothelial growth factor and interleukin-17 in patients with multiple myeloma].
Dong SS; Li GL; Yang J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):344-7. PubMed ID: 22541095
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of serum vascular endothelial growth factor and interleukin-6 in multiple myeloma].
Shen JK; Dong LH; Qi H; Zhang GS
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Feb; 30(1):68-71. PubMed ID: 15871192
[TBL] [Abstract][Full Text] [Related]
3. [Serum level of IL-17 in patients with multiple myeloma and its clinical significance].
Zhang XL; Zhang WH; Fan XH; Wei F; Zhang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):930-2. PubMed ID: 22931657
[TBL] [Abstract][Full Text] [Related]
4. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
5. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of serum vascular endothelial growth factor in patients with multiple myeloma].
Li X; Wei XZ; Liu JW; Geng CY; Chen WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):108-11. PubMed ID: 24598661
[TBL] [Abstract][Full Text] [Related]
7. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
8. [Expression Level and Clinical Significance of VEGF, IL-17, β2-MG and IL-35 in Patients with Multiple Myeloma].
Jin XN; Zhou BZ; Zhang DF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):192-196. PubMed ID: 29397842
[TBL] [Abstract][Full Text] [Related]
9. [Expressions of vascular endothelial growth factor and cyclooxygenase-2 in patients with multiple myeloma and its significance].
Bao HY; Zhu MQ; Jiang M; Dong NZ; Ruan CG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):99-101. PubMed ID: 19236756
[TBL] [Abstract][Full Text] [Related]
10. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of serum lactate dehydrogenase, β2-microglobulin and vascular endothelial growth factor level detection in patients with non-Hodgkin's lymphoma].
Duan Y; Li G; Hu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):608-10. PubMed ID: 22739165
[TBL] [Abstract][Full Text] [Related]
12. [Expression of serum vascular endothelial growth factor correlates with clinical outcome in multiple myeloma].
Usnarska-Zubkiewicz L; Mazur G; Wróbel T; Poreba M; Kuliczkowski K
Pol Arch Med Wewn; 2003 Jul; 110(1):719-24. PubMed ID: 14682206
[TBL] [Abstract][Full Text] [Related]
13. [Expression and clinical significance of vascular endothelial growth factor and its receptors in multiple myeloma].
Liu JR; Luo SK; Li J; Su C
Ai Zheng; 2007 Jun; 26(6):652-6. PubMed ID: 17562275
[TBL] [Abstract][Full Text] [Related]
14. [The significance of IGF-1, VEGF, IL-6 in multiple myeloma progression].
Guo YQ; Chen SL
Zhonghua Xue Ye Xue Za Zhi; 2006 Apr; 27(4):231-4. PubMed ID: 16875552
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
16. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
[TBL] [Abstract][Full Text] [Related]
17. [Serum levels of sVCAM-1, IL-18 and VEGF in patients with aplastic anemia and their clinical significance].
Liu RY; Wu YZ; Fan HL; Xu XY; Luo YG; Hu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):117-20. PubMed ID: 19236760
[TBL] [Abstract][Full Text] [Related]
18. IL-21 and other serum proinflammatory cytokine levels in patients with multiple myeloma at diagnosis.
Mehtap O; Atesoglu EB; Tarkun P; Hacihanefioglu A; Dolasik I; Musul MM
J Postgrad Med; 2014; 60(2):141-4. PubMed ID: 24823512
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival.
Alexandrakis MG; Passam FH; Sfiridaki K; Moschandrea J; Pappa C; Liapi D; Petreli E; Roussou P; Kyriakou DS
Leuk Res; 2004 Mar; 28(3):259-66. PubMed ID: 14687621
[TBL] [Abstract][Full Text] [Related]
20. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
Alexandrakis MG; Passam FH; Kyriakou DS; Christophoridou AV; Perisinakis K; Hatzivasili A; Foudoulakis A; Castanas E
Am J Hematol; 2004 Feb; 75(2):101-6. PubMed ID: 14755377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
